Anticoagulant Prescribing Patterns in New-Onset Atrial Fibrillation After Cardiac Surgery

Ann Thorac Surg. 2024 Apr;117(4):859-865. doi: 10.1016/j.athoracsur.2023.11.031. Epub 2023 Dec 9.

Abstract

Background: Postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery and is associated with an increased risk of thromboembolic stroke. Recommendations regarding the optimal anticoagulant, timing of initiation, and duration of therapy remain uncertain.

Methods: Administrative databases were used to include adult patients who presented with POAF after cardiac surgery between January 1, 2015, and December 31, 2020. Key exclusion criteria included preexisting atrial fibrillation, mechanical valve replacement, or anticoagulant prescription fill within 6 months before the index admission.

Results: A total of 3214 of patients were included, and 878 (27.3%) were prescribed an oral anticoagulant (OAC) on discharge, with 536 (61%) prescribed warfarin and 342 (39%) prescribed a direct OAC. More than half of the patients (56.1%) stopped their OAC by 6 months. There was no difference in stroke or systemic embolism at 30 days, 3 months, or 6 months between those with and without anticoagulation prescribed. However, those on any OAC had higher rates of any bleeding at all time points.

Conclusions: A minority of patients who presented with POAF after cardiac surgery were prescribed OAC, with warfarin being the most common agent. OAC initiation was associated with increased bleeding risk, warranting special consideration when assessing a patient's risk of stroke with the increased risk of bleeding, particularly in the postoperative period.

MeSH terms

  • Administration, Oral
  • Adult
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / drug therapy
  • Atrial Fibrillation* / epidemiology
  • Atrial Fibrillation* / etiology
  • Cardiac Surgical Procedures* / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Retrospective Studies
  • Risk Factors
  • Stroke* / epidemiology
  • Stroke* / etiology
  • Stroke* / prevention & control
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin